drugset / Trial / NCT00967928
Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
This Phase 1, single-site, dose-escalation study is being conducted to determine the maximum tolerated dose (MTD) of RAD001 as part of a specified combination regimen.
Timeline
- Start
- 2009-12
- Primary completion
- 2010-12
- Completion
- 2010-12
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |